FLAG chemotherapy followed by allogeneic stem cell transplant using nonmyeloablative conditioning induces regression of myelofibrosis with myeloid metaplasia.

Abstract	A 38-year-old woman with agnogenic myeloid metaplasia complicated by the poor prognostic factors of severe osteosclerosis, prominent hepatosplenomegaly, and profound anemia was treated with FLAG chemotherapy to decrease her organomegaly before undergoing a nonmyeloablative allogeneic stem cell transplant from a matched-sibling donor. The patient's pre- and post transplant course were complicated by an autoimmune disorder and her post transplant course was complicated by severe hepatic and gastrointestinal GVHD. A technetium-99m sulfur colloid scan 4 months post transplant and bone marrow studies 8 months post transplant demonstrated intramedullary hematopoiesis, complete resolution of marrow fibrosis, and partial resolution of osteosclerosis.
Authors	M L Tanner, C K Hoh, A Bashey, P Holman, C Sun, H E Broome, T Lane, E D Ball, E Carrier
Journal	Bone marrow transplantation (Bone Marrow Transplant) Vol. 32 Issue 6 Pg. 581-5 (Sep 2003) ISSN: 0268-3369 [Print] England
PMID	12953130 (Publication Type: Case Reports, Journal Article)
Chemical References	Immunosuppressive Agents Cytarabine Granulocyte Colony-Stimulating Factor Vidarabine
Topics	Adult Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use) Cytarabine (administration & dosage) Female Graft vs Host Disease (pathology) Granulocyte Colony-Stimulating Factor (administration & dosage) Hematopoiesis Hematopoietic Stem Cell Transplantation (adverse effects, methods) Humans Immunosuppressive Agents (therapeutic use) Osteosclerosis (diagnostic imaging) Primary Myelofibrosis (complications, diagnostic imaging, therapy) Radionuclide Imaging Remission Induction Splenomegaly Transplantation Conditioning (methods) Transplantation, Homologous Treatment Outcome Vidarabine (administration & dosage, analogs & derivatives)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!